Skip to content

Insider · CIK 0002065633

Subhashis Banerjee

officer

Files at ARTV (Artiva Biotherapeutics, Inc.). First filing Sep 4, 2026, latest Oct 6, 2026.

Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 2
$0 bought, $20k sold

Where the trades landed

Last year at the company this insider has traded most, with each buy and sell on the bar it happened.

ARTV: Artiva Biotherapeutics, Inc.

ARTVOct 9, 2026 · close 6.94

Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™

Signals

This insider’s open-market buys and sells, scored.

ScoreCompanyValueHoldingsPrice contextFiled
30Weak
ARTVsell 4
Artiva Biotherapeutics, Inc.
$7,514
1,099 shares
-1%+160% from low-47% from high
30Weak
ARTVsell 4
Artiva Biotherapeutics, Inc.
$12k
1,100 shares
-1%-

Transactions

Every row this insider has filed, newest first.

DateCompanyTransactionSharesPriceValueHoldings afterFiled
Oct 5, 2026ARTV
Artiva Biotherapeutics, Inc.
SOpen-market sale
Common Stock
-1,099$6.84$7,514169,8486 d ago
Sep 9, 2026ARTV
Artiva Biotherapeutics, Inc.
AGrant or award
Common Stock
+30,000$0.00$0170,94731 d ago
Sep 9, 2026ARTV
Artiva Biotherapeutics, Inc.
AGrant or award
Employee Stock Option (Right to Buy)derivative
+85,000$0.00$085,00031 d ago
Sep 3, 2026ARTV
Artiva Biotherapeutics, Inc.
SOpen-market sale
Common Stock
-1,100$11.16$12k140,94738 d ago
Apr 8, 2025ARTV
Artiva Biotherapeutics, Inc.
AGrant or award
Common Stock
+50,000$0.00$050,000Apr 25, 2025
Apr 8, 2025ARTV
Artiva Biotherapeutics, Inc.
AGrant or award
Employee Stock Option (Right to Buy)derivative
+80,000$0.00$080,000Apr 25, 2025

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.

Subhashis Banerjee: insider trades and track record | InsiderTell